SKVI and Quoin Poised to Tackle Opioid Crisis with Alternative Pain Therapies
- A possible larger role for leading drug manufacturers, and the resulting opioid epidemic, is met with increased public and government demands for alternative therapies
- The Skinvisible and Quoin merger, with expected completion in 2018, will create an enterprise positioned to disrupt the $6 billion U.S. opioid market by producing and delivering non-opioid alternatives for pain management
- Quoin’s QRX001 is slated to provide alternative and effective pain management in the post-surgical setting, where 50 percent of opioid addictions start
A recent article by the Washington Post
) addressed the opioid crisis, suggesting a larger role by leading pharmaceutical drug manufacturers than originally thought. The story alludes to the possibility that “drug manufacturers and distributors turned a willfully blind eye toward illegal drug trafficking.” In the midst of this, there is an opioid epidemic that has been deemed a national health emergency that results in 90 deaths per day (http://nnw.fm/V60zK
) and is growing exponentially, according to the Centers for Disease Control and Prevention.
There are increased incentives and growing public and FDA/government demands to address the crisis. Innovators vying to meet critical needs and to combat the opioid issue with alternative, non-addictive and effective products include Skinvisible, Inc. (OTCQB: SKVI
) and Quoin Pharmaceuticals Limited. As announced earlier this month, the two companies have entered a Letter of Intent for a proposed merger, with expected completion in early 2018, that will result in a new entity, Quoin Pharmaceuticals Inc. Upon completion of this merger, the new company (combining Quoin’s strengths of pharmaceutical development and Skinvisible’s innovative technologies that enhance delivery and product performance) has tremendous potential to address the significant needs of the pain management market.
One of the main areas of Quoin’s focus is to disrupt the opioid market (currently estimated at $6 billion annually in the U.S. alone) and produce and deliver to market non-opioid products that serve as effective and viable alternatives for the immense pain management market. This focus will include all areas of pain management, including critical needs in the post-surgical setting. At least 50 million U.S. surgeries require the use of post-operative pain management pharmaceuticals annually, and it is in the post-surgical setting that about 50 percent of opioid addictions begin.
To address the critical demands for effective alternatives to opioids, Quoin will launch one of its first lead products, QRX001, for effective treatment of post-surgical pain. The product, a transdermal NMDA receptor antagonist, delivers up to 72 hours of effective post-surgical pain relief. With the aim of providing alternatives to opioids as well as opiates, numerous clinical studies on QRX001 have shown that sub-anesthetic doses have resulted in a marked 24-hour reduction in PCA morphine consumption. In addition, clinical tests of the NMDA receptor antagonist generated superior results to any single existing product or combination and resulted in mild or absent adverse events, reduced post-surgical nausea and vomiting and reduced pain intensity.
With completion of the merger of Skinvisible and Quoin expected in early 2018, the synergies of the merged technologies, expertise and proven track records poise the new Quoin Pharmaceuticals with tremendous potential to address the needs of the immense pain market and tackle the opioid epidemic head-on.
For more information, visit the company’s website at www.Skinvisible.com